IGM Biosciences Total Liab Over Time
| IGMS Stock | USD 10.04 0.39 3.74% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out IGM Biosciences Performance and IGM Biosciences Correlation. IGM |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IGM Biosciences. If investors know IGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IGM Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.61) | Revenue Per Share 0.048 | Quarterly Revenue Growth 0.014 | Return On Assets (0.37) | Return On Equity (1.32) |
The market value of IGM Biosciences is measured differently than its book value, which is the value of IGM that is recorded on the company's balance sheet. Investors also form their own opinion of IGM Biosciences' value that differs from its market value or its book value, called intrinsic value, which is IGM Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IGM Biosciences' market value can be influenced by many factors that don't directly affect IGM Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IGM Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if IGM Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IGM Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare IGM Biosciences and related stocks such as Avidity Biosciences, Cerevel Therapeutics, and Cullinan Oncology LLC Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNA | 29.3 M | 29.3 M | 41.9 M | 38 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 162.3 M | 27.7 M | 46.1 M | 60.7 M | 127.8 M | 70.7 M |
| CGEM | 323 K | 323 K | 323 K | 1 M | 1.2 M | 1.2 M | 578.3 K | 55.3 M | 55.3 M | 140.4 M | 291 M | 11.8 M | 26.1 M | 30.3 M | 55.9 M |
| MLYS | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 34 M | 166.7 M | 10.5 M | 10 M |
| GLUE | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 98.1 M | 18.8 M | 71 M | 124.5 M | 73.8 M |
| DSGN | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 47.8 M | 8.4 M | 13.8 M | 12 M | 13.7 M |
| HOWL | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 148.3 M | 26.5 M | 37.9 M | 63.5 M | 51.5 M |
| IKNA | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 269.5 M | 40 M | 25.3 M | 22.3 M | 21.2 M |
| STOK | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 2.5 M | 4.3 M | 11.8 M | 21.1 M | 71.2 M | 68.8 M | 72.2 M |
| ERAS | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 69.1 M | 238.8 M | 44.9 M | 103.1 M | 78.6 M | 85.5 M |
| RVMD | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 73.9 M | 68 M | 92.7 M | 135.4 M | 126.7 M | 235.5 M | 247.3 M |
| BDTX | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 67.4 M | 209.3 M | 21.9 M | 491.5 M | 40.6 M | 41.8 M | 39.7 M |
| PASG | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 45.6 M | 4.3 M | 23.3 M | 36.4 M | 42.2 M | 39.3 M | 35 M |
IGM Biosciences and related stocks such as Avidity Biosciences, Cerevel Therapeutics, and Cullinan Oncology LLC Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| IGM Biosciences | IGMS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 10.04
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.